Evidence map›Paper›PMID 39301554›Full record

ArticleFrontiers in oncology2024

Case report: NUP98::LEDGF fusion gene drives malignant hematological tumor with mixed immunological phenotype.

Song Xue, Jia-Qi Chen, Tong Wang, Li-Na Zhang, Man Chen, Hui-Peng Sun, Xing-Yu Cao

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Song Xue *Department of Bone Marrow Transplant, Beijing Lu Daopei Hospital, Beijing, China.
Jia-Qi Chen *Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Tong WangDepartment of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Li-Na ZhangDivision of Pathology & Laboratory Medicine, Beijing Lu Daopei Hospital, Beijing, China.
Man ChenDivision of Pathology & Laboratory Medicine, Beijing Lu Daopei Hospital, Beijing, China.
Hui-Peng SunDivision of Pathology & Laboratory Medicine, Beijing Lu Daopei Hospital, Beijing, China.
Xing-Yu CaoDepartment of Bone Marrow Transplant, Hebei Yanda Lu Daopei Hospital, Langfang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is the first report of NUP98::LEDGF positive malignant hematological tumor expressing T cell and myeloid lineage antigens. Patients carrying this fusion gene have a high relapse rate and a poor prognosis, allo-HSCT may be an option to cure this disease. This patient underwent allo-HSCT, a relapse occurred three months post-transplantation. Subsequent screening at our hospital confirmed the presence of the NUP98::LEDGF fusion gene, salvage therapy was administered, followed by a successful second allo-HSCT. Furthermore, we included eight previously reported cases from the literature for analysis and discuss.

Indexed as

Allo-HSCTAMLmixed lineage leukaemia geneNUP98::LEDGFNUP98 rearrangementT-LBL

Identifiers

PMID39301554
PMCPMC11410684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.